Cooperative Patent Classification


Version: 2018.08
Loading Scheme...
CPC
COOPERATIVE PATENT CLASSIFICATION
A61P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS [2018-01]
NOTES

  • This subclass covers therapeutic activity of chemical compounds or medicinal preparations already classified as such in subclasses A61K or C12N, or in classes C01, C07 or C08
  • In this subclass, the term "drugs" includes chemical compounds or compositions with therapeutic activity.
  • In this subclass, therapeutic activity is classified in all appropriate places {to the extent of all the different therapeutic activities stated in the claims and also significantly disclosed as examples in the disclosure}.
  • Attention is drawn to cases where the subject of the invention concerns only specific therapeutic activity of chemical compounds or medical preparations, and the chemical structure, compound, mixture or composition of this subject of the invention is known. In such cases, classification is made in both subclass A61K and subclass A61P as invention information. In addition, if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is considered to represent information of interest for search, it may also be classified as additional information. {There is no classification in C01, C07, C08, C12N as additional information in CPC if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is known and classification is made in both subclass A61K and subclass A61P as invention information.}
  • The classification symbols of this subclass are not listed first when assigned to patent documents.
A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system [2018-01]
A61P 1/02
.
Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis [2018-01]
A61P 1/04
.
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants [2018-01]
A61P 1/06
.
Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia [2018-01]
A61P 1/08
.
for nausea, cinetosis or vertigo; Antiemetics [2018-01]
A61P 1/10
.
Laxatives [2018-01]
A61P 1/12
.
Antidiarrhoeals [2018-01]
A61P 1/14
.
Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents [2018-01]
A61P 1/16
.
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics [2018-01]
A61P 1/18
.
for pancreatic disorders, e.g. pancreatic enzymes [2018-01]
A61P 3/00
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) [2018-01]
A61P 3/02
.
Nutrients, e.g. vitamins, minerals [2018-01]
A61P 3/04
.
Anorexiants; Antiobesity agents [2018-01]
A61P 3/06
.
Antihyperlipidemics [2018-01]
A61P 3/08
.
for glucose homeostasis (pancreatic hormones A61P 5/48) [2018-01]
A61P 3/10
. .
for hyperglycaemia, e.g. antidiabetics [2018-01]
A61P 3/12
.
for electrolyte homeostasis [2018-01]
A61P 3/14
. .
for calcium homeostasis (vitamin D A61P 3/02; parathyroid hormones A61P 5/18; calcitonin A61P 5/22; osteoporosis A61P 19/10; bone metastasis A61P 35/04) [2018-01]
A61P 5/00
Drugs for disorders of the endocrine system [2018-01]
A61P 5/02
.
of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin [2018-01]
A61P 5/04
. .
for decreasing, blocking or antagonising the activity of the hypothalamic hormones [2018-01]
A61P 5/06
.
of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH [2018-01]
A61P 5/08
. .
for decreasing, blocking or antagonising the activity of the anterior pituitary hormones [2018-01]
A61P 5/10
.
of the posterior pituitary hormones, e.g. oxytocin, ADH [2018-01]
A61P 5/12
. .
for decreasing, blocking or antagonising the activity of the posterior pituitary hormones [2018-01]
A61P 5/14
.
of the thyroid hormones, e.g. T3, T4 [2018-01]
A61P 5/16
. .
for decreasing, blocking or antagonising the activity of the thyroid hormones [2018-01]
A61P 5/18
.
of the parathyroid hormones [2018-01]
A61P 5/20
. .
for decreasing, blocking or antagonising the activity of PTH [2018-01]
A61P 5/22
. .
for decreasing, blocking or antagonising the activity of calcitonin [2018-01]
A61P 5/24
.
of the sex hormones [2018-01]
A61P 5/26
. .
Androgens [2018-01]
A61P 5/28
. .
Antiandrogens [2018-01]
A61P 5/30
. .
Oestrogens [2018-01]
A61P 5/32
. .
Antioestrogens [2018-01]
A61P 5/34
. .
Gestagens [2018-01]
A61P 5/36
. .
Antigestagens [2018-01]
A61P 5/38
.
of the suprarenal hormones [2018-01]
A61P 5/40
. .
Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids [2018-01]
A61P 5/42
. .
for decreasing, blocking or antagonising the activity of mineralocorticosteroids [2018-01]
A61P 5/44
. .
Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids [2018-01]
A61P 5/46
. .
for decreasing, blocking or antagonising the activity of glucocorticosteroids [2018-01]
A61P 5/48
.
of the pancreatic hormones [2018-01]
A61P 5/50
. .
for increasing or potentiating the activity of insulin [2018-01]
A61P 7/00
Drugs for disorders of the blood or the extracellular fluid [2018-01]
A61P 7/02
.
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors [2018-01]
A61P 7/04
.
Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents [2018-01]
A61P 7/06
.
Antianaemics [2018-01]
A61P 7/08
.
Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P 27/04) [2018-01]
A61P 7/10
.
Antioedematous agents; Diuretics [2018-01]
A61P 7/12
.
Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P 5/10) [2018-01]
A61P 9/00
Drugs for disorders of the cardiovascular system [2018-01]
A61P 9/02
.
Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives [2018-01]
A61P 9/04
.
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure [2018-01]
A61P 9/06
.
Antiarrhythmics [2018-01]
A61P 9/08
.
Vasodilators for multiple indications [2018-01]
A61P 9/10
.
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis [2018-01]
A61P 9/12
.
Antihypertensives [2018-01]
A61P 9/14
.
Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers [2018-01]
A61P 11/00
Drugs for disorders of the respiratory system [2018-01]
A61P 11/02
.
Nasal agents, e.g. decongestants [2018-01]
A61P 11/04
.
for throat disorders [2018-01]
A61P 11/06
.
Antiasthmatics [2018-01]
A61P 11/08
.
Bronchodilators [2018-01]
A61P 11/10
.
Expectorants [2018-01]
A61P 11/12
.
Mucolytics [2018-01]
A61P 11/14
.
Antitussive agents [2018-01]
A61P 11/16
.
Central respiratory analeptics [2018-01]
A61P 13/00
Drugs for disorders of the urinary system [2018-01]
A61P 13/02
.
of urine or of the urinary tract, e.g. urine acidifiers [2018-01]
A61P 13/04
.
for urolithiasis [2018-01]
A61P 13/06
.
Anti-spasmodics [2018-01]
A61P 13/08
.
of the prostate [2018-01]
A61P 13/10
.
of the bladder [2018-01]
A61P 13/12
.
of the kidneys [2018-01]
A61P 15/00
Drugs for genital or sexual disorders (for disorders of sex hormones A61P 5/24); Contraceptives [2018-01]
A61P 15/02
.
for disorders of the vagina [2018-01]
A61P 15/04
.
for inducing labour or abortion; Uterotonics [2018-01]
A61P 15/06
.
Antiabortive agents; Labour repressants [2018-01]
A61P 15/08
.
for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis [2018-01]
A61P 15/10
.
for impotence [2018-01]
A61P 15/12
.
for climacteric disorders [2018-01]
A61P 15/14
.
for lactation disorders, e.g. galactorrhoea [2018-01]
A61P 15/16
.
Masculine contraceptives [2018-01]
A61P 15/18
.
Feminine contraceptives [2018-01]
A61P 17/00
Drugs for dermatological disorders [2018-01]
A61P 17/02
.
for treating wounds, ulcers, burns, scars, keloids, or the like [2018-01]
A61P 17/04
.
Antipruritics [2018-01]
A61P 17/06
.
Antipsoriatics [2018-01]
A61P 17/08
.
Antiseborrheics [2018-01]
A61P 17/10
.
Anti-acne agents [2018-01]
A61P 17/12
.
Keratolytics, e.g. wart or anti-corn preparations [2018-01]
A61P 17/14
.
for baldness or alopecia [2018-01]
A61P 17/16
.
Emollients or protectives, e.g. against radiation [2018-01]
A61P 17/18
.
Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q 17/00) [2018-01]
A61P 19/00
Drugs for skeletal disorders [2018-01]
A61P 19/02
.
for joint disorders, e.g. arthritis, arthrosis [2018-01]
A61P 19/04
.
for non-specific disorders of the connective tissue [2018-01]
A61P 19/06
.
Antigout agents, e.g. antihyperuricemic or uricosuric agents [2018-01]
A61P 19/08
.
for bone diseases, e.g. rachitism, Paget's disease [2018-01]
A61P 19/10
. .
for osteoporosis [2018-01]
A61P 21/00
Drugs for disorders of the muscular or neuromuscular system [2018-01]
A61P 21/02
.
Muscle relaxants, e.g. for tetanus or cramps [2018-01]
A61P 21/04
.
for myasthenia gravis [2018-01]
A61P 21/06
.
Anabolic agents (androgens A61P 5/26) [2018-01]
A61P 23/00
Anaesthetics [2018-01]
A61P 23/02
.
Local anaesthetics [2018-01]
A61P 25/00
Drugs for disorders of the nervous system [2018-01]
A61P 25/02
.
for peripheral neuropathies [2018-01]
A61P 25/04
.
Centrally acting analgesics, e.g. opioids [2018-01]
A61P 25/06
.
Antimigraine agents [2018-01]
A61P 25/08
.
Antiepileptics; Anticonvulsants [2018-01]
A61P 25/10
. .
for petit-mal [2018-01]
A61P 25/12
. .
for grand-mal [2018-01]
A61P 25/14
.
for treating abnormal movements, e.g. chorea, dyskinesia [2018-01]
A61P 25/16
. .
Anti-Parkinson drugs [2018-01]
A61P 25/18
.
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia [2018-01]
A61P 25/20
.
Hypnotics; Sedatives [2018-01]
A61P 25/22
.
Anxiolytics [2018-01]
A61P 25/24
.
Antidepressants [2018-01]
A61P 25/26
.
Psychostimulants, e.g. nicotine, cocaine [2018-01]
A61P 25/28
.
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia [2018-01]
A61P 25/30
.
for treating abuse or dependence [2018-01]
A61P 25/32
. .
Alcohol-abuse [2018-01]
A61P 25/34
. .
Tobacco-abuse [2018-01]
A61P 25/36
. .
Opioid-abuse [2018-01]
A61P 27/00
Drugs for disorders of the senses [2018-01]
A61P 27/02
.
Ophthalmic agents [2018-01]
A61P 27/04
. .
Artificial tears; Irrigation solutions [2018-01]
A61P 27/06
. .
Antiglaucoma agents or miotics [2018-01]
A61P 27/08
. .
Mydriatics or cycloplegics [2018-01]
A61P 27/10
. .
for accommodation disorders, e.g. myopia [2018-01]
A61P 27/12
. .
for cataracts [2018-01]
A61P 27/14
. .
Decongestants or antiallergics [2018-01]
A61P 27/16
.
Otologicals [2018-01]
A61P 29/00
Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs) [2018-01]
A61P 29/02
.
without antiinflammatory effect [2018-01]
A61P 31/00
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics [2018-01]
A61P 31/02
.
Local antiseptics [2018-01]
A61P 31/04
.
Antibacterial agents [2018-01]
A61P 31/06
. .
for tuberculosis [2018-01]
A61P 31/08
. .
for leprosy [2018-01]
A61P 31/10
.
Antimycotics [2018-01]
A61P 31/12
.
Antivirals [2018-01]
A61P 31/14
. .
for RNA viruses [2018-01]
A61P 31/16
. . .
for influenza or rhinoviruses [2018-01]
A61P 31/18
. . .
for HIV [2018-01]
A61P 31/20
. .
for DNA viruses [2018-01]
A61P 31/22
. . .
for herpes viruses [2018-01]
A61P 33/00
Antiparasitic agents [2018-01]
A61P 33/02
.
Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis [2018-01]
A61P 33/04
. .
Amoebicides [2018-01]
A61P 33/06
. .
Antimalarials [2018-01]
A61P 33/08
. .
for Pneumocystis carinii [2018-01]
A61P 33/10
.
Anthelmintics [2018-01]
A61P 33/12
. .
Schistosomicides [2018-01]
A61P 33/14
.
Ectoparasiticides, e.g. scabicides [2018-01]
A61P 35/00
Antineoplastic agents [2018-01]
A61P 35/02
.
specific for leukemia [2018-01]
A61P 35/04
.
specific for metastasis [2018-01]
A61P 37/00
Drugs for immunological or allergic disorders [2018-01]
A61P 37/02
.
Immunomodulators [2018-01]
A61P 37/04
. .
Immunostimulants [2018-01]
A61P 37/06
. .
Immunosuppressants, e.g. drugs for graft rejection [2018-01]
A61P 37/08
.
Antiallergic agents (antiasthmatic agents A61P 11/06; ophthalmic antiallergics A61P 27/14) [2018-01]
A61P 39/00
General protective or antinoxious agents [2018-01]
A61P 39/02
.
Antidotes [2018-01]
A61P 39/04
.
Chelating agents [2018-01]
A61P 39/06
.
Free radical scavengers or antioxidants [2018-01]
A61P 41/00
Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution [2018-01]
A61P 43/00
Drugs for specific purposes, not provided for in groups A61P 1/00-A61P 41/00 [2018-01]
NOTE

  • Classification is only made in this group when a specific therapeutic activity for a chemical compound or medicinal preparation has been clearly disclosed, the specific therapeutic activity not being appropriate to any of groups A61P 1/00 - A61P 41/00.